Ewing sarcoma of the hands and feet: Outcome and prognostic factors of a rare subsite in a low-middle income country

Ganguly, Shuvadeep ; Sasi, Archana ; Nagpal, Chitrakshi ; Biswas, Bivas ; Agarwala, Sandeep ; Pushpam, Deepam ; Biswas, Ahitagni ; Kumar, Venkatesan Sampath ; Kapoor, Love ; Khan, Shah Alam ; Jain, Vishesh ; Bakhshi, Sameer (2025) Ewing sarcoma of the hands and feet: Outcome and prognostic factors of a rare subsite in a low-middle income country Pediatric Hematology Oncology Journal, 10 (1). pp. 24-32. ISSN 2468-1245

Full text not available from this repository.

Official URL: https://doi.org/10.1016/j.phoj.2025.02.004

Related URL: http://dx.doi.org/10.1016/j.phoj.2025.02.004

Abstract

Background The small bones of the hand and feet represent a rare site of Ewing sarcoma (ES) origin. This study presents a real-world dataset describing the clinical presentation, survival outcomes, and their determinants in this subsite. Methods This is a single-institutional retrospective study of patients with ES originating from the hands/feet (ES-HF), treated between 2003 and 2018. Clinical/demographic details and survival outcomes were retrieved from medical records. Descriptive statistics were used to summarize baseline characteristics. Prognostic factors for event-free survival (EFS) and overall survival (OS) were identified by Cox regression. The clinical features and outcomes were compared between ES-HF and ES-others (ES from other sites) in the cohort. Results Of 859 ES cases, 28 (3.2 %) patients had ES-HF including four ES-hands (0.5 %) and 24 ES-feet (2.8 %). The calcaneum was the most common site [11 of 28 cases; 39.3 %]. More than half of the patients (53.6 %) had metastatic disease at presentation. In comparison with ES-others, ES-HF had longer median symptom duration [12 versus 4 months; p < 0.001] and smaller tumor diameter [5.5 versus 9 cm; p < 0.001]. The median EFS and OS of the cohort were 30.5 and 39.13 months respectively. Only local therapy receipt was associated with improved EFS (multivariable HR:0.013; 95%CI:0.001–0.158; p < 0.001) and OS (multivariable HR:0.028; 95 % CI:0.003–0.272; p = 0.002). Patients receiving radiotherapy alone had inferior OS compared to those receiving surgery alone. (HR: 9.22; 95 % CI: 1.12–76.31; p = 0.039) Conclusion ES-HF is a rare ES subsite. Although indolent, metastases are common at presentation. Meticulous local control can improve survival in both localized and metastatic disease for this subsite.

Item Type:Article
Source:Copyright of this article belongs to Elsevier Science.
Keywords:Ewing sarcoma; Primitive neuroectodermal tumor; Childhood cancer; Pediatric oncology; Low-middle income country; Distal extremities; Hand and feet
ID Code:138545
Deposited On:21 Aug 2025 06:22
Last Modified:21 Aug 2025 06:22

Repository Staff Only: item control page